Phase II clinical trial - Sein métastatique triple négatif

Sein métastatique triple négatif
Ouvert depuis le: 11.30.2022
Site: Saint-Cloud
Public cible
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
Description de l'essai

The main purpose of this study is to evaluate bintrafusp alfa monotherapy in participants with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a centralized reverse transcriptase-polymerase chain reaction (RT-PCR) test.